title: Double-blind, crossover, placebo-controlled trial of bromocriptine in patients with sleep bruxism.
abstract: This study was designed to assess the effects of bromocriptine, a dopamine D2 receptor agonist, on sleep bruxism. Seven otherwise healthy patients with severe and frequent sleep bruxism participated in this randomized, double-blind, placebo-controlled study. The study used a crossover design that included 2 weeks of active treatment or placebo with a washout period of 1 week. To further evaluate whether bromocriptine influences striatal D2 receptor binding, we used iodine-123-iodobenzamide single photon emission computed tomography (SPECT) under both placebo and bromocriptine regimens. Bromocriptine did not reduce the frequency of episodes of bruxism during sleep (mean +/- SEM, 9.0 +/- 1.0 and 9.6 +/- 1.5 bruxism episodes per hour for placebo and bromocriptine, respectively) or the amplitude of masseter muscle contractions (root mean square values, 48.2 +/- 15.5 microV and 46.9 +/- 12.7 microV for placebo and bromocriptine, respectively). SPECT also failed to reveal that either treatment had any influence on striatal D2 binding (values for total binding in counts/pixel, 1.80 [1.72-1.93] and 1.79 [1.56-1.87] for placebo and bromocriptine, respectively). This study shows that a nightly dose of bromocriptine does not exacerbate or reduce sleep bruxism motor activity.
authors.affiliation: Center d'étude du sommeil, Hôpital du Sacré-Coeur de Montréal, Québec, Canada.
authors.forename: G J
authors.initials: GJ
authors.lastname: Lavigne
authors.forename: J P
authors.initials: JP
authors.lastname: Soucy
authors.forename: F
authors.initials: F
authors.lastname: Lobbezoo
authors.forename: C
authors.initials: C
authors.lastname: Manzini
authors.forename: P J
authors.initials: PJ
authors.lastname: Blanchet
authors.forename: J Y
authors.initials: JY
authors.lastname: Montplaisir
mesh_terms: D000328:Adult; D001971:Bromocriptine / Q000009:adverse effects / Q000627:therapeutic use*; D002012:Bruxism / Q000188:drug therapy*; D018592:Cross-Over Studies; D018491:Dopamine Agonists / Q000009:adverse effects / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D017448:Receptors, Dopamine D2 / Q000187:drug effects / Q000378:metabolism; D012890:Sleep / Q000187:drug effects; D012894:Sleep Stages / Q000187:drug effects
chemical_list: D018491:Dopamine Agonists; D017448:Receptors, Dopamine D2; D001971:Bromocriptine